# OnCo record belzutifan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/belzutifan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "belzutifan" ;
  schema:name "Belzutifan"@en ;
  schema:description "Belzutifan is the first HIF-2α inhibitor, born from Nobel-winning biology, and is now approved after kidney cancer surgery with pembrolizumab."@en ;
  schema:url <https://onco.cc/drugs/belzutifan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Belzutifan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27456641> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Belzutifan> ;
  onco:status "approved" ;
  onco:modality "Small-molecule HIF-2α inhibitor" ;
  schema:alternateName "Welireg" ;
  onco:approval "US 2021: VHL-associated RCC, CNS haemangioblastoma, pNET", "US 2023: Advanced RCC after PD-1/PD-L1 and VEGF-TKI", "US 2026: Adjuvant clear-cell RCC with pembrolizumab", "EU 2025: ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional)" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/clear-cell-rcc/>, <https://onco.cc/cancers/spinal-cord-tumours/>, <https://onco.cc/cancers/pancreatic-net/>, <https://onco.cc/cancers/hereditary-ppgl/>, <https://onco.cc/cancers/metastatic-ppgl/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/hif2a/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/nct07049926/>, <https://onco.cc/trials/nct03634540/>, <https://onco.cc/trials/nct04924075/>, <https://onco.cc/trials/nct05468697/>, <https://onco.cc/trials/nct04626479/>, <https://onco.cc/trials/nct04586231/>, <https://onco.cc/trials/nct05899049/>, <https://onco.cc/trials/nct04976634/>, <https://onco.cc/trials/nct04626518/>, <https://onco.cc/trials/nct06428396/>, <https://onco.cc/trials/nct07405164/>, <https://onco.cc/trials/nct04489771/> .